ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

CMPX Compass Therapeutics Inc

2.00
-0.05 (-2.44%)
Pre Market
Last Updated: 07:05:00
Delayed by 15 minutes

Period:

Draw Mode:

Volume 2,000
Bid Price 1.95
Ask Price 2.00
News -
Day High

Low
1.15

52 Week Range

High
3.62

Day Low
Company Name Stock Ticker Symbol Market Type
Compass Therapeutics Inc CMPX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.05 -2.44% 2.00 07:05:00
Open Price Low Price High Price Close Price Prev Close
2.05
Trades Volume Avg Volume 52 Week Range
1 2,000 - 1.15 - 3.62
Last Trade Time Type Quantity Stock Price Currency
06:45:28 formt 2,000 $ 2.00 USD

Compass Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
261.35M 127.49M - 0 -39.23M -0.31 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Compass Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No CMPX Message Board. Create One! See More Posts on CMPX Message Board See More Message Board Posts

Historical CMPX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week2.182.281.952.12204,840-0.18-8.26%
1 Month1.832.341.682.08333,4930.179.29%
3 Months1.442.341.151.76506,6060.5638.89%
6 Months2.042.341.151.72438,588-0.04-1.96%
1 Year3.143.621.152.36435,463-1.14-36.31%
3 Years4.105.651.152.70311,942-2.10-51.22%
5 Years4.105.651.152.70311,942-2.10-51.22%

Compass Therapeutics Description

Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. The company has drugged over 40 immune targets and generated a diverse pipeline of monoclonal and multispecific therapeutic candidates with potential to transform care for patients with cancer or autoimmune diseases.

Your Recent History

Delayed Upgrade Clock